You are here

STTR Phase I: Intelligent Low-Toxicity Nanoparticles for Cancer Diagnosis and Treatment

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0930673
Agency Tracking Number: 0930673
Amount: $150,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: MM
Solicitation Number: NSF 08-608
Solicitation Year: 2009
Award Year: 2009
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 946856804
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Franklin Kroh
 (785) 537-0179
Business Contact
 Franklin Kroh
Title: PhD
Phone: (785) 537-0179
Research Institution
 Kansas State University
 Paul Lowe
2 Fairchild Hall
Manhattan, KS 66506 1103
United States

 (785) 532-6817
 Nonprofit College or University

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Technology Transfer (STTR) Phase I project focuses on synthesis and delivery of nanoparticles for determination of the progression of cancer. Besides diagnosis, the nanoplatform offers the treatment option of directing high- temperature therapy specifically to the tumor, without harming healthy tissue. The nanoplatform contains a central iron/iron oxide/gold core/shell nanoparticle, plus the ability to identify which of four cancer-specific enzymes in the patient?s body are abnormally active. The activity of these four enzymes indicates the progression of cancer (Stage I, Stage II, Stage III, or Stage IV). The broader impacts of this research are earlier diagnosis of cancer, and more effective treatment of cancer. Cancer is the second largest cause of death in developed countries, accounting for nearly 20% of all deaths. Early detection of cancer is essential even before
anatomic anomalies are visible. A major challenge in cancer diagnosis is detection of tumors at an early stage for maximum therapeutic benefit. An example is breast cancer where mammography requires more than a million cells for accurate clinical diagnosis. Offering better techniques to cancer centers and their patients could detect these abnormalities in the hundreds to thousands of cells stage, greatly improving treatment success. The functionalized nanoparticles will be more selective towards cancer cells than currently available technology, enabling diagnosis by spectroscopic methods including MRI at earlier stages of the cancers progression. In addition to enabling earlier detection, these materials also have potential for breakthroughs in treatment methods.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government